{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:25:29Z","timestamp":1787063129530,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100022720","name":"Health Bureau","doi-asserted-by":"publisher","award":["CID-HKU-2-12"],"award-info":[{"award-number":["CID-HKU-2-12"]}],"id":[{"id":"10.13039\/100022720","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40261-026-01575-7","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:18:41Z","timestamp":1783081121000},"page":"1047-1065","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of the Approved Nirmatrelvir\/Ritonavir and Molnupiravir Regimens for Treatment of Mild\/Moderate Laboratory-Confirmed SARS-CoV-2 Infection in Patients Aged 18\u201364 Years in Hong Kong: A Population-Based Cohort Study"],"prefix":"10.1007","volume":"46","author":[{"given":"George N.","family":"Okoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Cowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"1575_CR1","unstructured":"National Institutes of Health. COVID-19 treatment guidelines. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK570371\/pdf\/Bookshelf_NBK570371.pdf. Accessed 2 Sept 2024."},{"key":"1575_CR2","unstructured":"Lam C, Patel P. Nirmatrelvir\u2013ritonavir. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK585126\/."},{"key":"1575_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105555","volume":"211","author":"J Li","year":"2023","unstructured":"Li J, Wang Y, Solanki K, et al. Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses. Antiviral Res. 2023;211:105555.","journal-title":"Antiviral Res"},{"key":"1575_CR4","doi-asserted-by":"crossref","unstructured":"Sheahan TP, Sims AC, Zhou ST, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12(541):eabb5883.","DOI":"10.1126\/scitranslmed.abb5883"},{"issue":"7","key":"1575_CR5","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1002\/jmv.27730","volume":"94","author":"S Masyeni","year":"2022","unstructured":"Masyeni S, Iqhrammullah M, Frediansyah A, et al. Molnupiravir: a lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2\u2014a narrative review. J Med Virol. 2022;94(7):3006\u201316.","journal-title":"J Med Virol"},{"issue":"5","key":"1575_CR6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.molcel.2020.07.027","volume":"79","author":"F Robson","year":"2020","unstructured":"Robson F, Khan KS, Le TK, et al. Coronavirus RNA proofreading: molecular basis and therapeutic targeting. Mol Cell. 2020;79(5):710\u201327.","journal-title":"Mol Cell"},{"key":"1575_CR7","unstructured":"United States Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Lagevrio\u2122 (molnupiravir) capsules. United States Food and Drug Administration. https:\/\/www.fda.gov\/media\/155054\/download. Published 2023. Accessed 26 July 2023."},{"key":"1575_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100602","volume":"30","author":"AK Wai","year":"2023","unstructured":"Wai AK, Chan CY, Cheung AW, et al. Association of molnupiravir and nirmatrelvir-ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. Lancet Reg Health Western Pacific. 2023;30:100602.","journal-title":"Lancet Reg Health Western Pacific"},{"issue":"4","key":"1575_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.7326\/M22-3057","volume":"176","author":"EYF Wan","year":"2023","unstructured":"Wan EYF, Yan VKC, Mok AHY, et al. Effectiveness of molnupiravir and nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a target trial emulation study. Ann Intern Med. 2023;176(4):505\u201314.","journal-title":"Ann Intern Med"},{"issue":"10359","key":"1575_CR10","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","volume":"400","author":"CKH Wong","year":"2022","unstructured":"Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022;400(10359):1213\u201322.","journal-title":"Lancet"},{"key":"1575_CR11","doi-asserted-by":"crossref","unstructured":"Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;22(12):1681\u201393.","DOI":"10.1016\/S1473-3099(22)00507-2"},{"issue":"3","key":"1575_CR12","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1093\/cid\/ciac687","volume":"76","author":"TC Yip","year":"2023","unstructured":"Yip TC, Lui GC, Lai MS, et al. Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19). Clin Infect Dis. 2023;76(3):e26\u201333.","journal-title":"Clin Infect Dis"},{"key":"1575_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100969","volume":"43","author":"B Yang","year":"2024","unstructured":"Yang B, Lin Y, Xiong W, et al. Comparison of control and transmission of COVID-19 across epidemic waves in Hong Kong: an observational study. Lancet Reg Health Western Pacific. 2024;43:100969.","journal-title":"Lancet Reg Health Western Pacific"},{"issue":"9596","key":"1575_CR14","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"11","key":"1575_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.32923","volume":"4","author":"SS Boon","year":"2021","unstructured":"Boon SS, Wong MCS, Ng RWY, et al. Seroprevalence of unidentified SARS-CoV-2 infection in Hong Kong during 3 pandemic waves. JAMA Netw Open. 2021;4(11):e2132923.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"1575_CR16","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","volume":"22","author":"ME McMenamin","year":"2022","unstructured":"McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022;22(10):1435\u201343.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1575_CR17","first-page":"209","volume":"7","author":"J Cui","year":"2007","unstructured":"Cui J. QIC program and model selection in GEE analyses. Stand Genomic Sci. 2007;7(2):209\u201320.","journal-title":"Stand Genomic Sci"},{"issue":"2","key":"1575_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1515\/ijb-2020-0045","volume":"17","author":"K Selig","year":"2020","unstructured":"Selig K, Shaw P, Ankerst D. Bayesian information criterion approximations to Bayes factors for univariate and multivariate logistic regression models. Int J Biostat. 2020;17(2):241\u201366.","journal-title":"Int J Biostat"},{"issue":"2","key":"1575_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1037\/a0027127","volume":"17","author":"SI Vrieze","year":"2012","unstructured":"Vrieze SI. Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC). Psychol Methods. 2012;17(2):228\u201343.","journal-title":"Psychol Methods"},{"issue":"2","key":"1575_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2307\/2344179","volume":"128","author":"WG Cochran","year":"1965","unstructured":"Cochran WG, Chambers SP. The planning of observational studies of human populations. J Roy Stat Soc. 1965;128(2):234\u201366.","journal-title":"J Roy Stat Soc"},{"key":"1575_CR21","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511712074","volume-title":"Evaluating clinical and public health interventions: a practical guide to study design and statistics","author":"MH Katz","year":"2010","unstructured":"Katz MH. Evaluating clinical and public health interventions: a practical guide to study design and statistics. London: Cambridge University Press; 2010."},{"issue":"1","key":"1575_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/bja\/aet290","volume":"112","author":"GN Okoli","year":"2014","unstructured":"Okoli GN, Sanders RD, Myles P. Demystifying propensity scores. Br J Anaesth. 2014;112(1):13\u20135.","journal-title":"Br J Anaesth"},{"issue":"8","key":"1575_CR23","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1017\/S095026881500309X","volume":"144","author":"HS Bond","year":"2016","unstructured":"Bond HS, Sullivan SG, Cowling BJ. Regression approaches in the test-negative study design for assessment of influenza vaccine effectiveness. Epidemiol Infect. 2016;144(8):1601\u201311.","journal-title":"Epidemiol Infect"},{"issue":"10","key":"1575_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1080\/21548331.1967.11706652","volume":"2","author":"W Kalow","year":"1967","unstructured":"Kalow W. How genetic factors affect individual drug responses. Hosp Pract. 1967;2(10):92\u20133.","journal-title":"Hosp Pract"},{"key":"1575_CR25","doi-asserted-by":"crossref","unstructured":"Stielow M, Witczynska A, Kubryn N, Fijalkowski L, Nowaczyk J, Nowaczyk A. The bioavailability of drugs\u2014the current state of knowledge. Molecules. 2023;28(24).","DOI":"10.3390\/molecules28248038"},{"issue":"1","key":"1575_CR26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-023-01619-w","volume":"8","author":"Q Zhao","year":"2023","unstructured":"Zhao Q, Chen Y, Huang W, Zhou H, Zhang W. Drug-microbiota interactions: an emerging priority for precision medicine. Signal Transduct Target Ther. 2023;8(1):386.","journal-title":"Signal Transduct Target Ther"},{"key":"1575_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-38180-9","volume-title":"The use of drugs","author":"W Modell","year":"1957","unstructured":"Modell W, Place DJ. Factors modifying drug action. In: The use of drugs. Berlin, Heidelberg: Springer; 1957."},{"key":"1575_CR28","doi-asserted-by":"crossref","unstructured":"Niederberger E, Parnham MJ. The impact of diet and exercise on drug responses. Int J Mol Sci. 2021;22(14):7692.","DOI":"10.3390\/ijms22147692"},{"issue":"7","key":"1575_CR29","doi-asserted-by":"publisher","first-page":"e2324963","DOI":"10.1001\/jamanetworkopen.2023.24963","volume":"6","author":"CP Sjaarda","year":"2020","unstructured":"Sjaarda CP, Lau L, Simpson JT, et al. Prevalence of low-frequency, antiviral resistance variants in SARS-CoV-2 isolates in Ontario, Canada, 2020\u20132023. JAMA Netw Open. 2020;6(7):e2324963.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"1575_CR30","doi-asserted-by":"publisher","first-page":"e2435431","DOI":"10.1001\/jamanetworkopen.2024.35431","volume":"7","author":"TJ Tamura","year":"2024","unstructured":"Tamura TJ, Choudhary MC, Deo R, et al. Emerging SARS-CoV-2 resistance after antiviral treatment. JAMA Netw Open. 2024;7(9):e2435431.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"1575_CR31","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.vaccine.2021.01.032","volume":"39","author":"GN Okoli","year":"2009","unstructured":"Okoli GN, Racovitan F, Abdulwahid T, Righolt CH, Mahmud SM. Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: a systematic review and meta-analysis of the evidence from test-negative design studies after the 2009\/10 influenza pandemic. Vaccine. 2009;39(8):1225\u201340.","journal-title":"Vaccine"},{"issue":"2","key":"1575_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/019262339502300202","volume":"23","author":"J Caldwell","year":"1995","unstructured":"Caldwell J, Gardner I, Swales N. An introduction to drug disposition: the basic principles of absorption, distribution, metabolism, and excretion. Toxicol Pathol. 1995;23(2):102\u201314.","journal-title":"Toxicol Pathol"},{"issue":"6","key":"1575_CR33","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1177\/00970002042006005","volume":"42","author":"MN Martinez","year":"2002","unstructured":"Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002;42(6):620\u201343.","journal-title":"J Clin Pharmacol"},{"issue":"15","key":"1575_CR34","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397\u2013408.","journal-title":"N Engl J Med"},{"issue":"13","key":"1575_CR35","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","volume":"390","author":"J Hammond","year":"2024","unstructured":"Hammond J, Fountaine RJ, Yunis C, et al. Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19. N Engl J Med. 2024;390(13):1186\u201395.","journal-title":"N Engl J Med"},{"issue":"4","key":"1575_CR36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1370\/afm.3120","volume":"22","author":"GN Okoli","year":"2024","unstructured":"Okoli GN, Askin N, Rabbani R. Nirmatrelvir\/ritonavir regimen for mild\/moderately severe COVID-19: a rapid review with meta-analysis and trial sequential analysis. Ann Fam Med. 2024;22(4):336\u201346.","journal-title":"Ann Fam Med"},{"key":"1575_CR37","doi-asserted-by":"crossref","unstructured":"Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509\u201320.","DOI":"10.1056\/NEJMoa2116044"},{"issue":"8","key":"1575_CR38","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cmi.2023.04.014","volume":"29","author":"Y Gao","year":"2023","unstructured":"Gao Y, Liu M, Li Z, Xu J, Zhang J, Tian J. Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials. Clin Microbiol Infect. 2023;29(8):979\u201399.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"1575_CR39","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/jac\/dkae163","volume":"79","author":"YM Mesfin","year":"2024","unstructured":"Mesfin YM, Blais JE, Kibret KT, Tegegne TK, Cowling BJ, Wu P. Effectiveness of nirmatrelvir\/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies. J Antimicrob Chemother. 2024;79(9):2119\u201331.","journal-title":"J Antimicrob Chemother"},{"key":"1575_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev-publhealth-032315-021353","volume":"37","author":"JA Casey","year":"2016","unstructured":"Casey JA, Schwartz BS, Stewart WF, Adler NE. Using electronic health records for population health research: a review of methods and applications. Annu Rev Public Health. 2016;37:61\u201381.","journal-title":"Annu Rev Public Health"},{"issue":"11","key":"1575_CR41","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/oxfordjournals.aje.a009758","volume":"149","author":"M Salas","year":"1999","unstructured":"Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol. 1999;149(11):981\u20133.","journal-title":"Am J Epidemiol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01575-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01575-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01575-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:32:46Z","timestamp":1787059966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01575-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1575"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01575-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BJC consults for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Novavax, Pfizer, Roche, and Sanofi Pasteur. All other authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approvals for this study were obtained from the Institutional Review Board of The University of Hong Kong and The Hospital Authority Hong Kong West Cluster (reference number HKU\/HA HKW IRB: UW 20-341), and the study was performed in accordance with the standards of ethics outlined in the\n                      Declaration of Helsinki\n                      .","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data collection process was part of the Government of Hong Kong public health responses to the COVID-19 pandemic, and therefore, informed consent from individual study participants was not required.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Restrictions apply to the availability of the data used for this study. Authors must not transmit or release the data, in whole or in part, and in whatever form or media, or to any other parties or place outside of Hong Kong and must fully comply with the duties under the law relating to the protection of personal data, including those under the Personal Data (Privacy) Ordinance and its principles in all aspects.","order":6,"name":"Ethics","label":"Consent Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GNO: Conceptualisation, Methodology, Data curation, Formal analysis, Visualisation, Validation, Original manuscript drafting, Reviewing & editing of the submitted manuscript. YL: Data curation, Visualisation, Reviewing & editing of the submitted manuscript. PW: Visualisation, Reviewing & editing of the submitted manuscript. BJC: Conceptualisation, Visualisation, Supervision, Reviewing & editing of the submitted manuscript. All authors read and approved the final version of the manuscript and agree to be accountable for the work.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}